durvalumab

AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC
Endpoints
Fri, 05/12/17 - 09:40 am
AstraZeneca
clinical trials
durvalumab
Imfinzi
non-small cell lung cancer
Checkpoint inhibitors set to face off in bladder cancer
BioPharma Dive
Wed, 02/8/17 - 09:48 am
bladder cancer
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Roche
Tecentriq
AstraZeneca
durvalumab
AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights Opdivo, Keytruda
Fierce Pharma
Tue, 02/7/17 - 10:25 am
immuno-oncology
AstraZeneca
durvalumab
Pascal Soriot
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
AstraZeneca angles for more competitive position in immuno-oncology
BioPharma Dive
Thu, 01/19/17 - 11:19 am
AstraZeneca
immuno-oncology
tremelimumab
durvalumab
AstraZeneca delays PD-L1 data in rejig of phase 3 program
Fierce Biotech
Tue, 01/17/17 - 10:02 am
AstraZeneca
anti-PD-L1
clinical trials
tremelimumab
durvalumab
Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?
Endpoints
Sun, 12/11/16 - 11:57 am
AstraZeneca
durvalumab
anti-PD-L1
bladder cancer
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
Market Realist
Mon, 11/21/16 - 11:39 am
AstraZeneca
anti-PD-L1
durvalumab
Opdivo
Keytruda
Tecentriq
Bristol-Myers Squibb
Roche
Merck
Here's Why AstraZeneca Dipped 14.2% in October
Motley Fool
Thu, 11/10/16 - 10:22 am
AstraZeneca
AZD9412
durvalumab
Brilinta
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
Endpoints
Fri, 10/28/16 - 10:12 am
FDA
AstraZeneca
durvalumab
clinical trials
head and neck cancer
Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data
Seeking Alpha
Sun, 09/18/16 - 09:54 am
Amgen
biosimilars
AstraZeneca
anti-PD-L1
ABP 501
Humira
durvalumab
AstraZeneca Rides High, Fueled by Brexit, Bristol-Myers Failure
Yahoo/Bloomberg
Fri, 08/12/16 - 11:02 am
AstraZeneca
Brexit
Bristol-Myers Squibb
Opdivo
durvalumab
lung cancer
AstraZeneca gets a boost from durvalumab PhIII chatter as pipeline wear and tear starts to show
Endpoints
Fri, 08/12/16 - 09:52 am
AstraZeneca
durvalumab
lung cancer
AstraZeneca wins FDA breakthrough status for key cancer drug
Yahoo/Reuters
Wed, 02/17/16 - 10:32 am
AstraZeneca
FDA
breakthrough status
durvalumab
bladder cancer
anti-PD-L1
AstraZeneca's cancer checkpoint combo looks promising in small lung cancer study
Fierce Biotech
Tue, 02/9/16 - 09:00 am
AstraZeneca
durvalumab
tremelimumab
metastatic non-small cell lung cancer
AstraZeneca hit with setback as durvalumab falls further behind on lung cancer
Fierce Biotech
Sat, 12/19/15 - 11:28 am
AstraZeneca
durvalumab
PDL-1 inhibitors
lung cancer
AstraZeneca cancer drug may not be so fast getting to market
Yahoo/Reuters
Thu, 11/5/15 - 09:50 am
AstraZeneca
durvalumab
AstraZeneca halts a pair of lung cancer trials over a safety scare
Fierce Biotech
Fri, 10/9/15 - 10:03 am
AstraZeneca
lung cancer
clinical trials
durvalumab
AZD9291
AstraZeneca ties up with little Mirati on another PD-L1 combo trial
Fierce Biotech
Thu, 08/6/15 - 08:27 am
AstraZeneca
PD-1 inhibitors
durvalumab
MedImmune
Mirati Therapeutics